Perspective Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 16, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 16, 2026
CATX$0.86+1.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Stockholders’ Equity
(In thousands, except shares)
| Common Stock | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Shares · Amount · Additional Paid-in Capital · Accumulated Other Comprehensive Income (Loss) · Accumulated Deficit · Total | ||||||||||
| Balances at December 31, 20231 | 28,180,985 | $28 | $227,591 | $ | - | $(152,440) | $75,179 | |||
| Issuance of common stock and Pre-funded Warrants, net1,2 | 42,163,012 | 42 | 288,013 | - | - | 288,055 | ||||
| Cancellation of fractional shares due to the 1-for-10 reverse stock split | (114) | - | (1) | - | - | (1) | ||||
| Issuance of common stock pursuant to exercise of options1 | 304,795 | - | 1,253 | - | - | 1,253 | ||||
| Issuance of stock pursuant to exercise of common stock warrants1 | 22,786 | - | 125 | - | - | 125 | ||||
| Unrealized loss on available-for-sale securities | (51) | - | (51) | |||||||
| Share-based compensation1 | - | - | 5,387 | - | - | 5,387 | ||||
| Net loss | - | - | - | - | (79,279) | (79,279) | ||||
| Balances at December 31, 2024 | 70,671,464 | $70 | $522,368 | $(51) | $(231,719) | $290,668 | ||||
| Issuance of common stock pursuant to exercise of options | 141,297 | - | 371 | - | - | 371 | ||||
| Issuance of common stock pursuant to the exercise of Pre-funded Warrants, net2 | 145,852 | 1 | (1) | - | - | - | ||||
| Issuance of common stock pursuant to the ATM, net2 | 3,379,377 | 3 | 9,983 | - | - | 9,986 | ||||
| Unrealized gain on available-for-sale securities | 161 | - | 161 | |||||||
| Share-based compensation | - | - | 8,966 | - | - | 8,966 | ||||
| Net loss | - | - | - | - | (103,121) | (103,121) | ||||
| Balances at December 31, 2025 | 74,337,990 | $74 | $541,687 | $110 | $(334,840) | $207,031 | ||||
Amounts for prior periods presented have been retroactively adjusted to reflect the 1-for-10 reverse stock split effected on June 14, 2024. See Note 1 for details.
See Note 3, Investments and Agreements, for additional information.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.